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Abstract
The pre-operative prediction of prognostic tumour features in the radical prostatectomy specimen
using routine clinicopathological variables remains limited. The present study evaluated the
predictive value of the cell-cycle protein p27kip1, the proliferation marker MIB-1, and the cell-
adhesion protein CD44s, determined on the diagnostic needle biopsy of asymptomatic men
screened for prostate cancer. Of 81 screen-detected prostate cancers, representative biopsy cores
and matched radical prostatectomy specimens were immunohistochemically stained for these
tissue markers. Conventional pre-operative and post-operative clinicopathological variables were
assessed and cancers were divided according to a validated tumour classification model
(potentially harmless, clinically significant). Low (<50%) p27kip1 expression, high (i10%)
MIB-1 expression, and low (<25%) CD44s expression were considered adverse prognostic signs.
Binary logistic regression analysis was performed to assess the most valuable predictors of
clinically significant disease. An adverse prognostic immunostaining assessment on the biopsy was
found in 10 (12.3%), 17 (21.0%), and 25 (30.9%) cases for p27kip1, MIB-1, and CD44s,
respectively. The concordance in tissue marker assessment between the biopsy specimen and
matched radical prostatectomy specimens was low for all three. The positive predictive value
(PPV) of p27kip1 was 90.0%, remarkably higher than that of MIB-1 and CD44s (41.2% and
52.0%, respectively), indicating that a low radical prostatectomy p27kip1 score is expected if the
biopsy p27kip1 score is low. Logistic regression analysis revealed that biopsy Gleason score
(p<0.01) and p27kip1 assessment (p<0.01) remained the only significant predictors of clinically
significant disease. All cases with low p27kip1 expression were found to have clinically significant
disease after radical prostatectomy. The assessment of p27kip1 in the biopsy specimen might thus
assist in distinguishing between potentially aggressive and potentially non-aggressive disease in
prostate cancer screening. Copyright # 2002 John Wiley & Sons, Ltd.
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Introduction
Despite prognostic information gained from serum
prostate-specific antigen (PSA), clinical tumour stage,
and tumour grade assessed on prostatic needle bio-
psies, the accuracy of predicting prostate cancer tumour
characteristics in the radical prostatectomy specimen
and with this, the final outcome of screen-detected
prostate cancer, remains limited [1–4]. The vast major-
ity of cancers are diagnosed within the PSA range
3.0–9.9 ng/ml, with biopsy Gleason scores 6 or 7, and
with clinical tumour stage T1c–T2 [5,6], but the
biological behaviour of these tumours is highly vari-
able. Some might have been treated unnecessarily as
the post-operative prognostic tumour features proved
highly favourable, while others might have too
advanced disease to be cured. It is therefore appro-
priate to seek to refine the prognostic information
gained from pretreatment variables, and from prostate
cancer biopsy specimens in particular.
Recently, several immunohistochemical studies have
demonstrated that the cell-cycle protein p27kip1, the
proliferation marker Ki-67 (MIB-1), and the cell-
adhesion protein CD44s have independent prognostic
value with respect to disease recurrence and patient
survival after radical prostatectomy [7–13]. Potentially,
these tissue markers might help in differentiating
aggressive from non-aggressive cancers before defini-
tive treatment. In the present study, we assessed whe-
ther the immunohistochemical expression of these
markers on the diagnostic needle biopsy was represen-
tative of that in matched radical prostatectomy speci-
mens. We examined the predictive value of these tissue
markers for well-established prognostic factors such as
pathological tumour stage, tumour grade, and tumour
volume in the radical prostatectomy specimen. It was
anticipated that the tumour marker thus identified as
most suitable for application on the needle biopsy
might give the clinician additional information on
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tumour aggressiveness and patient prognosis on a
pretreatment basis.
Materials and methods
Patients
Between 1 January 1998 and 15 September 1999, 99
consecutively admitted men within the screening arm
of the European randomized study of screening for
prostate cancer (ERSPC) underwent bilateral pelvic
lymph-node dissection and radical prostatectomy at the
University Hospital Rotterdam. In all screened parti-
cipants, prostate cancer was diagnosed on ultrasound-
guided sextant transrectal biopsy of the prostate,
prompted by an elevated (i3.0 ng/ml) serum-PSA
level. Neo-adjuvant (hormonal) treatment was not
applied in any of the patients. No patient had pelvic
lymph-node metastatic disease, either on intra-
operative examination of frozen tissue sections, or
after the examination of paraffin slides. Of 81
surgically treated patients, tissue from both the
diagnostic needle biopsy and the matched radical
prostatectomy specimens was available for (immuno-
histochemical) analysis. Pre-operative PSA and clinical
tumour stage were obtained from the ERSPC data-
base.
Pathological tissue examination
All sextant diagnostic biopsy cores were labelled and
processed separately. The biopsy cores were routinely
fixed in 10% buffered formalin (pH 7.5), embedded in
paraffin wax, freshly cut into 4 mm tissue sections,
and mounted on glass slides. Haematoxylin and eosin
(H&E) slides of three subsequent levels of the needle
biopsy were histologically examined and a Gleason
score was assigned by a specialist genito-urinary
pathologist (THvdK) [14].
Radical prostatectomy specimens were fixed simi-
larly, schematically cut [15], embedded in paraffin wax,
cut into 4 mm tissue sections, and mounted on glass
slides. The tumour was staged according to the
TNM’97 system and the Gleason score was deter-
mined. All tumour areas were traced and outlined on
the slides. Detailed prostate maps were developed to
illustrate the size, extent, and location of the prostate
tumour and its different histopathological grades
(Figure 1). Morphometric analysis was performed to
assess the tumour volume as described by Hoedemaeker
et al. [16]. Finally, cancers were categorized according
to a previously developed and validated prognostic
tumour classification model, including pathological
tumour stage, tumour volume, and the proportion of
high-grade cancer [17]. According to this classification
model, organ-confined cancers with a tumour volume
less than 0.5 ml, without Gleason growth patterns 4
and 5, were considered potentially ‘harmless’, while all
other cancers were arbitrarily assessed as ‘clinically
significant’ [17,18].
Selection of the most representative slides
The selection of the most representative biopsy core was
made by an experienced pathologist (THvdK). The
selection was based on the assumption that the observed
tumour features within the slide would be most
predictive of patient outcome. The most representative
core was the core with the highest Gleason score or
when the Gleason score was not different between
biopsies, the core with the most extensive tumour
involvement. The biopsy slides were stored for a
maximum of 2.5 years in a dark environment at room
temperature until immunostaining was performed.
The most representative slides within the radical
prostatectomy were similarly selected. One to three
paraffin blocks with tumour tissue most representative
of the whole tumour within the radical prostatectomy
specimen were selected for immunohistochemical ana-
lysis. Using radical prostatectomy maps, the site,
range, and trajectory of the individual biopsy cores,
and that of the most representative biopsy core in
particular, were reconstructed (Figure 1). In doing so,
one may determine whether the representative biopsy
needle hit or did not hit the representative tumour
parts within the radical prostatectomy specimen.
Immunostaining
Slides from biopsies and radical prostatectomy speci-
mens were immunohistochemically stained according
to similar protocols. Tissues from the radical prosta-
tectomy specimens were freshly cut, while those of the
biopsy specimens were retrieved from storage. After
deparaffinization through xylene and 100% ethanol,
endogenous peroxidase activity was blocked by immer-
sing the slides for 20 min in 3% H2O2 in methanol. The
slides were placed in a 10 mmol/l citrate buffer at
pH 6.0. Antigen retrieval was performed in a micro-
wave oven at 700 W for 15 min. After cooling, the
slides were pre-incubated with 10% normal goat serum
in PBS/BSA 5%. The slides were incubated overnight
at 4uC with the primary antibody MIB-1 (Immuno-
tech, France) at an optimal dilution of 1 : 3000, p27kip1
(Novocastra, UK) at 1 : 40, or CD44s (Bender Med-
Systems, Austria) at 1 : 200 in PBS/BSA 5%. Negative
controls were included with each batch of slides. For
MIB-1 and p27kip1, the conventional avidin–biotin
complex method was applied. Briefly, a 30 min incu-
bation with biotinylated goat-anti mouse antibody
(Biogenex, San Ramon, USA) was followed by a
30 min incubation with streptavidin–peroxidase com-
plex (Biogenex). For CD44s, the catalysed signal
amplification (CSA, K1500, DAKO) system was used.
After overnight incubation with the primary antibody,
a 15 min incubation with a linking antibody was
followed by a 15 min incubation with streptavidin–
biotin complex, a 15 min incubation with an amplifica-
tion reagent, and a final 15 min incubation with
streptavidin–peroxidase. In all slides, the antibody–
antigen binding was visualized with diaminobenzidine
hydrochloride (Fluka, Neu-Ulm, Germany) with 0.08%
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H2O2 for 7 min. The specimens were counterstained
with haematoxylin, dehydrated, and covered.
Quantitation
All slides were assessed by two independent observers
(ANV, BWvR) without knowledge of matched biopsy
or radical prostatectomy tumour features. In the event
of discrepancy between observers, the slides were
reassessed in a combined session. Agreement between
observers occurred in over 80% of cases for all three
tissue markers. All selected sections contained benign
prostatic glands, which could serve as internal positive
controls. For all three tissue markers, the immuno-
staining quantitation was similar for both the biopsy
specimens and the radical prostatectomy specimens.
For p27kip1, nuclear staining was assessed by estimat-
ing a positive-to-total ratio as previously described [7].
A tumour was considered ‘high’ for p27kip1 expression
if 50% or more nuclei showed positive immunostaining,
and ‘low’ if a positive-to-total ratio of less than 50%
was recorded [7] (Figure 2). In the case of tumour
heterogeneity, those parts within the tumour that
showed the lowest positive-to-total ratio were assessed.
For MIB-1, nuclear staining was assessed by estimating
the percentage of MIB-1-positive cells [7]. Tumours
with 10% or more nuclei positive for MIB-1 were
considered ‘high’ for MIB-1 expression, whereas those
with less than 10% of MIB-1 positivity were assessed
‘low’ for MIB-1 expression. If the tumour exhibited
heterogeneous MIB-1 expression, the area with the
highest density of MIB-1-positive cells was selected.
Slides stained with CD44s were assessed according
to the percentage of cells showing positive membranous
immunostaining (Figure 2). Since less than 25%
negative immunostaining has been reported to be
most predictive of clinical progression after radical
prostatectomy [12], this cut-off point was taken for
statistical analysis. Slides were assessed as having ‘low’
(<25%) or ‘high’ (i25%) tumour CD44s expression. A
tumour CD44s score was obtained by taking the lowest
assessed score within the tumour sections.
The concordance in tissue marker assessment
between the biopsy and the radical prostatectomy
specimen was determined for all three tissue markers.
An adverse prognostic assessment (low p27kip1, high
MIB-1, low CD44s) was considered a positive test
outcome. Sensitivity, specificity, and the positive (PPV)
and negative predictive values (NPV) of tissue marker
assessment were calculated. Similar analyses were
performed with respect to biopsy tissue marker assess-
ment and clinical significance of disease.
Statistical analysis
Statistical analysis was performed using SPSS 9.0 (SPSS
Inc., Chicago, IL, USA). The association between
p27kip1, MIB-1, and CD44s expression on the biopsy
and conventional clinicopathological parameters was
evaluated using the Pearson chi-squared (x2) test. The
pre-operative PSA level was categorized as 3.0–3.9 ng/
ml, 4.0–5.9 ng/ml, 6.0–9.9 ng/ml, or i10.0 ng/ml; clin-
ical tumour stage as T1c or T2a–b; Gleason score as 2–6,
7, or 8–10; and the proportion of high-grade cancer as
0%, 0–9%, 10–49%, or i50%. Post-operative variables
were categorized as listed in Table 1.
Binary logistic regression analysis was performed to
assess the statistical significance of pre-operative vari-
ables. Clinically significant disease was taken as the
dependent variable, while conventional pre-operative
clinicopathological variables, and the expression level
of tissue markers on the biopsy, were taken as cova-
riates. Variables that were not statistically significant at
the univariate level were removed, while controlling for
Table 1. The association of the expression of p27kip1, MIB-1, and CD44s with pathological tumour stage, Gleason
score, and the tumour classification model. Numbers in parentheses are percentages
Tissue marker expression on the diagnostic biopsy
Radical prostatectomy
tumour features
p27kip1 MIB-1 CD44s
TotalLow (<50%) High (i50%) Low (<10%) High (i10%) Low (<25%) High (i25%)
Pathological stage*
pT2 5 (50.0) 64 (90.1) 56 (87.5) 13 (76.5) 20 (80.0) 49 (87.5) 69
pT3a 4 (40.0) 6 (8.5) 7 (10.9) 3 (17.6) 4 (16.0) 6 (10.7) 10
pT3b–4 1 (10.0) 1 (10.0) 1 (1.6) 1 (5.9) 1 (4.0) 1 (1.8) 2
Gleason score
2–6 2 (20.0) 51 (71.8) 46 (71.9) 7 (41.1) 12 (48.0) 41 (73.2) 53
7 (3+4) 5 (50.0) 17 (23.9) 13 (20.3) 9 (52.9) 11 (44.0) 11 (19.6) 22
7 (4+3) 3 (30.0) 3 (4.2) 5 (7.8) 1 (5.9) 2 (8.0) 4 (7.1) 6
Tumour classification
Harmless{ 0 (0.0) 23 (32.4) 20 (31.3) 3 (17.6) 4 (16.0) 19 (33.9) 23
Clinically significant{ 10 (100.0) 48 (67.6) 44 (68.8) 14 (82.4) 21 (84.0) 37 (66.1) 58
Total 10 71 64 17 25 56 81
*pTNM 1997.
{Possibly harmless disease: organ-confined cancers with a tumour volume of less than 0.5 ml, without Gleason growth patterns 4 and 5.
{Clinically significant disease: all others.
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other variables (backward elimination method). For-
ward stepwise elimination was performed to verify that
the same parameters remained of prognostic signifi-
cance in the final models. The assumption that no
association existed between the variables evaluated
(H0) was rejected (H1) if p<0.05.
Results
Patient characteristics
All 81 patients had clinically localized disease at the
time of diagnosis. The median serum PSA level was
5.2 ng/ml (range 3.0–15.1), and 71 (87.7%) had a PSA
level between 3.0 and 9.9 ng/ml. A total of 48 (59.3%)
and 18 (22.2%) men had a Gleason score of 6 or 7 on
the biopsy, respectively, and 11 (13.6%) a Gleason
score of 7 (4+3) or 8. Within the radical prostatec-
tomy specimen, 69 (85.2%) cancers were organ-
confined, 10 (12.3%) had extraprostatic extension, and
2 (2.5%) showed extensive infiltrating disease (Table 1).
The Gleason score was 2–6 in 53 (65.4%) and a
dominant Gleason growth pattern of 4 or 5 was seen in
6 (7.4%). According to the tumour classification model,
23 (28.4%) cases were considered ‘harmless’ and 58
(71.6%) ‘clinically significant’. Using prostate maps, in
14 (17.3%) cases the selected representative biopsy
needle did not hit the site of the prostate that was
thought to contain the representative sections within
the tumour (Figure 1).
Immunostaining assessment
Of 81 patients, 10 (12.3%) and 35 (43.2%) had low
tumour p27kip1 expression on the diagnostic needle
biopsy and radical prostatectomy specimen, respec-
tively. These figures were 17 (21.0%) and 26 (32.1%)
for high MIB-1 expression, and 25 (30.9%) and 26
(32.1%) for low CD44s expression. Table 2 shows the
sensitivity, specificity, PPV, and NPV of tissue marker
assessment. The sensitivity of tissue marker assessment
was low for all three tissue markers, implying that a
substantial proportion of cases were incorrectly desig-
nated a favourable prognostic outcome. Nine of 10
(PPV=90.0%) cases with low biopsy p27kip1 expression
had low p27kip1 expression in the prostate, whereas 26
of 71 cases designated as having high tumour p27kip1
expression pre-operatively changed category after
radical prostatectomy (NPV=63.4%). The PPV of
Figure 1. A prostate map showing the site, range, and trajec-
tory of the most representative biopsy core (IV) and two other
biopsy cores (II and V), as well as the location of the tumour in
the prostate and its corresponding grade of differentiation
according to Gleason [14]. The tumour is shown in black
(Gleason growth pattern 3) and grey (Gleason growth pattern
4). Prostate sections C1 and D4 were assessed as the most
representative of the tumour in the prostate, whereas biopsy
core IV contained the highest amount of cancer (approximately
60%). Biopsy V missed the tumour completely, while biopsy II
was only marginally involved with cancer (less than 10%)
Table 2. Sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) of the expres-
sion of p27kip1, MIB-1, and CD44s as determined on the
biopsy specimen. Low (less than 50%) tumour p27kip1,
high (10% and more) tumour MIB-1, and low (less than
25%) tumour CD44s expression on the biopsy were
considered positive test outcomes (i.e. adverse prognos-
tic indicators)
Biopsy tissue
marker Sensitivity* Specificity{ PPV{ NPV}
p27kip1 expression 25.7% 97.8% 90.0% 63.4%
MIB-1 expression 26.9% 81.8% 41.2% 70.3%
CD44s expression 50.0% 78.2% 52.0% 76.8%
*Sensitivity=number of adverse prognostic assessments determined on the
biopsy divided by the number of adverse prognostic outcomes in the
radical prostatectomy specimen.
{Specificity=number of favourable prognostic assessments on the biopsy
divided by the number of favourable prognostic outcomes in the radical
prostatectomy specimen.
{PPV=the proportion of men with an adverse prognostic assessment on
the biopsy who also had an adverse prognostic outcome in the radical
prostatectomy.
}NPV=proportion of men with a favourable assessment on the biopsy
who also had a favourable outcome in the radical prostatectomy specimen.
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MIB-1 and CD44s expression was lower than p27kip1,
while the NPVs were only slightly higher (Table 2).
The expression of p27kip1 and CD44s was almost
absent (i.e. low) in intraluminar growing strands of
cribriform and intraductal prostate cancer (Figure 2).
Association of tissue marker expression with
pre- and post-operative variables
The association of the expression of the tissue markers
on the biopsy with pre-operative and post-operative
clinicopathological parameters is given in Table 3.
While p27kip1 expression was highly associated with
most of the pre-operative and post-operative variables,
as well as with MIB-1 and CD44s expression, the latter
two tissue markers were not, or were only weakly,
correlated with these same parameters (Table 3). Low
expression of p27kip1 had a high predictive value for
the presence of clinically significant disease (Table 1).
In fact, all cases with low pre-operative p27kip1 turned
out to have clinically significant disease after radical
prostatectomy (PPV=100.0%). For biopsy Gleason
scores of 7 or higher, all cases but one (22 of 23) were
found to have clinically significant disease after radical
prostatectomy (PPV=95.7%). Logistic regression ana-
lysis revealed that biopsy Gleason score (p<0.01) and
low expression of p27kip1 (p<0.01) on the biopsy
were most valuable as predictors of clinically signifi-
cant disease, though with wide confidence intervals
(Table 4). CD44s and MIB-1 expression on the biopsy
did not remain in the final models as independent
predictors of clinically significant disease.
Discussion
In prostate cancer screening, no reliable method exists
today that may identify the patients with non-
aggressive disease and those with fatal disease beyond
cure. Such tools are required, for it is considered that a
A B
C D
Figure 2. Immunostaining images of tissue marker expression on the diagnostic needle biopsy (r400). (A) Low (<50%) tumour
p27kip1 expression; (B) high (i50%) tumour p27kip1 expression; (C) low (<25%) tumour CD44s expression; (D) high (i25%)
tumour CD44s expression
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substantial proportion of screen-detected prostate
cancers may have been overdiagnosed (and subse-
quently overtreated), while others may not have been
detected (and treated) early enough. Unfortunately, the
predictive value of conventional clinicopathological
parameters for powerful prognosticators such as
pathological tumour stage and lymph-node metastatic
disease remains limited, and with this, the identifica-
tion of aggressive but curable cancers.
Recent studies demonstrated that the expression of
the cell-cycle protein p27kip1, the proliferation marker
MIB-1, and the cell-adhesion protein CD44s within
tumours was of prognostic importance in men treated
with radical prostatectomy, in addition to grading and
staging [7–13]. Valuable tissue markers assessed on the
diagnostic needle biopsy may aid in the selection of
patients to undergo (or to have withheld) radical
surgery for clinically localized prostate cancer. In the
current study we report a relatively poor concordance
for the expression level of p27kip1, MIB-1, and CD44s
on the diagnostic needle biopsy and representative
sections of the corresponding radical prostatectomy
specimen (Table 2). The sensitivity was low for all
three tissue markers, indicating that prognostically
adverse tumour areas within the prostate were missed
in a substantial number of cases. These results are in
line with those of previously published and similarly
performed studies [19–21]. Furthermore, the PPV was
high only for low p27kip1 expression (PPV=90%),
while comparably low for MIB-1 and CD44s (41.2%
and 52.0%, respectively).
Our analysis by logistic regression showed that
biopsy p27kip1 expression and biopsy Gleason score
were significant predictors of clinically significant
disease (Table 4). Despite wide confidence intervals
due to small patient series, the observation of low
p27kip1 expression on the diagnostic biopsy might thus
be indicative of biologically aggressive disease. In our
study, all men with a low (<50%) tumour p27kip1 score
on the biopsy were found to have clinically significant
disease after radical prostatectomy, using the defini-
tions of the tumour classification model. On the other
hand, a high (i50%) biopsy p27kip1 score poorly
predicted the presence of a prostate cancer with
prognostically favourable tumour features. Therefore,
the assessment of p27kip1 expression on the biopsy is
not helpful in identifying patients who are most likely
to benefit from conservative treatment and surveil-
lance. Moreover, our study did not provide data on
whether ‘aggressive’ cancers identified by a low biopsy
tumour p27kip1 may be cured by the currently available
treatment options, or on the other hand, may already
be beyond the reach of cure.
The interpretation of our results may be limited by
various factors. Multifocality and tumour heterogene-
ity may have contributed to the sampling error of the
diagnostic needle biopsy, and to the poor concordance
of tissue marker assessment between the biopsy and the
radical prostatectomy specimen. As only one or two
biopsy cores per patient were stained immunohisto-
chemically, i.e. those that were assumed to be most
representative within the biopsy sextant, tissue marker
assessment may not have reflected the entire primary
tumour within the prostate. On the other hand, it is
not likely that an adverse prognostic immunostaining
assessment would have been found in one of the ‘non-
representative’ biopsy cores, especially when taking
into account that these were mostly of lower grade and
of low tumour volume. The frequency of adverse
prognostic immunostaining assessments was low in our
screened population (e.g. 12.3% for low p27kip1 expres-
sion) and as a consequence, definite conclusions on the
predictive value of tissue markers may only be given
using larger patient series. It is likely that the pro-
portion of adverse prognostic indicators may have
Table 3. Correlation of p27kip1, MIB-1, and CD44s with
pre-operative clinicopathological parameters and tumour
characteristics determined on the radical prostatectomy
specimen. The figures presented are p values
Tissue marker expression on the
diagnostic biopsy
Variable p27kip1* MIB-1{ CD44s{
PSA level <0.01 0.06 ns
Clinical tumour stage 0.01 ns ns
Biopsy Gleason score <0.01 <0.01 ns
Biopsy high-grade cancer <0.01 0.01 0.02
Biopsy p27kip1 – 0.05 <0.01
Biopsy MIB-1 0.05 – 0.01
Biopsy CD44s <0.01 0.01 –
Pathological tumour stage <0.01 ns ns
Prostatic Gleason score <0.01 ns ns
Tumour classification model <0.01 ns ns
*Dichotomized as low p27kip1 (less than 50%) and high p27kip1 (50% and
more) expression.
{Dichotomized as high MIB-1 (10% and more) and low MIB-1 (less than
10%) expression.
{Dichotomized as low CD44s (less than 25%) and high CD44s (25% and
more) expression.
ns=not significant.
Table 4. Logistic regression analysis for the prediction of
‘clinically significant’ disease using conventional clinico-
pathological variables and the expression of p27kip1,
MIB-1, and CD44s on the diagnostic needle biopsy
Logistic regression analysis
eb 95% CI p value
PSA level – – ns
Clinical tumour stage – – ns
Biopsy Gleason score 13.01 1.78–96.03 <0.01
Proportion high-grade – – ns
Biopsy p27kip1* 8.97 1.03–76.92 <0.01
Biopsy MIB-1{ – – ns
Biopsy CD44s{ – – ns
95% CI=95% confidence interval; eb=odds ratio; ns=not significant.
*Low p27kip1 (less than 50%) expression.
{High MIB-1 (10% and more) expression.
{Low CD44s (less than 25%) expression.
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been higher in other patient groups that lacked
the favourable prognostic features observed in our
screening group. Finally, the long-term prognostic
significance of our tumour classification model remains
to be established. It might well be that some men
classified as having clinically significant disease in our
study population would never have experienced signs
or symptoms of prostate cancer; and conversely, that
some men designated as having potentially harmless
disease might still have had clinically manifest disease
if not treated.
At present, the routinely performed diagnostic
technique of systematic sextant prostate biopsy has a
limited ability to predict the tumour characteristics in
the prostate gland, and with this, the expected
biological course of disease. The present study has
provided some further evidence that tissue marker
assessment on the biopsy, p27kip1 in particular, might
help in discriminating between potentially aggressive
and potentially non-aggressive cancers in prostate
cancer screening. Before its clinical application is
considered, our promising results on the value of
p27kip1 protein expression on prostatic needle biopsies
in men with screen-detected prostate cancer will have
to be confirmed, preferably in prospective, multi-
institutional studies with larger numbers of patients.
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